Mbx biosciences announces once-weekly canvuparatide achieved primary endpoint in phase 2 trial with 63% responder rate at 12 weeks; 79% responder rate at 6 months in open-label extension

Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (prn) and further improvement sustained in open-label extension (ole)
MBX Ratings Summary
MBX Quant Ranking